Table 2.
Genotype frequencies of four single‐nucleotide polymorphisms in DNMT1 according to the status of cardiovascular autonomic neuropathy in the overall individuals with type 1 diabetes
| SNP | Without CAN | With CAN | OR (95% CI) | P‐value |
|---|---|---|---|---|
| n | 238 | 121 | ||
| DNMT1 | ||||
| rs17291414 | ||||
| GG | 0.570 | 0.534 | 1.07 (0.61–1.43) | 0.73 |
| GA | 0.343 | 0.375 | ||
| AA | 0.087 | 0.091 | ||
| MAF | 0.258 | 0.278 | ||
| rs11085721 | ||||
| GG | 0.713 | 0.591 | 1.50 (0.59–1.72) | 0.08 |
| GC | 0.266 | 0.375 | ||
| CC | 0.021 | 0.033 | ||
| MAF | 0.154 | 0.221 | ||
| rs7254567 | ||||
| GG | 0.362 | 0.273 | 1.19 (0.55–1.45) | 0.38 |
| GA | 0.473 | 0.568 | ||
| AA | 0.165 | 0.159 | ||
| MAF | 0.401 | 0.443 | ||
| rs10854076 | ||||
| GG | 0.787 | 0.750 | 1.26 (0.49–1.65) | 0.70 |
| GC | 0.193 | 0.239 | ||
| CC | 0.020 | 0.011 | ||
| MAF | 0.116 | 0.130 | ||
Odds ratio (OR) for the minor allele determined in logistic regression in a co‐dominant model analysis adjusted for glycated hemoglobin, triglyceride concentrations, estimated glomerular filtration rate, the presence of hypertension and use of medicines (angiotensin‐converting enzyme inhibitors and statins). P ≤ 0.01 is considered significant. CAN, cardiovascular autonomic neuropathy; CI, confidence interval; MAF, minor allele frequency; SNP, single‐nucleotide polymorphism.